This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Immunization  • Genetic Counseling/ Testing/ Therapy  • Genetics, Other  • Neurology  • Alzheimer Disease  • Alert me on articles by topic

Commentary by Roger N. Rosenberg, MD

JAMA. 2005;294(18):2352-2353.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ARCHIVES OF NEUROLOGY

Risk Factors Associated With β-Amyloid_(1-42) Immunotherapy in Preimmunization Gene Expression Patterns of Blood Cells

Margot O’Toole, PhD; Derek B. Janszen, PhD; Donna K. Slonim, PhD; Padmalatha S. Reddy, PhD; Debra K. Ellis, BS; Holly M. Legault, BS; Andrew A. Hill, PhD; Maryann Z. Whitley, PhD; William M. Mounts, MS; Krystyna Zuberek, BS; Frederick W. Immermann, PhD; Ronald S. Black, MD; Andrew J. Dorner, PhD

Background  A phase 2a, double-blind, placebo-controlled, multicenter study was conducted to evaluate safety, tolerability, and pilot efficacy of immunization with β-amyloid_(1-42) in patients with Alzheimer disease. Six immunizations were planned but were halted when meningoencephalitis was recognized as an adverse event in 6% of immunized patients.

Objective  To identify biomarkers associated with both the risk of meningoencephalitis and antibody responsiveness.

Participants  One hundred fifty-three patients with mild to moderate Alzheimer disease.

Main Outcome Measure  Association between response . . . [Full Text of this Article]

RELATED ARTICLE

Risk Factors Associated With -Amyloid_(1-42) Immunotherapy in Preimmunization Gene Expression Patterns of Blood Cells
Margot O’Toole, Derek B. Janszen, Donna K. Slonim, Padmalatha S. Reddy, Debra K. Ellis, Holly M. Legault, Andrew A. Hill, Maryann Z. Whitley, William M. Mounts, Krystyna Zuberek, Frederick W. Immermann, Ronald S. Black, and Andrew J. Dorner
Arch Neurol. 2005;62(10):1531-1536.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Time Will Be of the Essence in Treating Alzheimer Disease
Rosenberg
JAMA 2006;296:327-329.
FULL TEXT  

Treating Alzheimer disease: time matters.
Rosenberg
Arch Neurol 2006;63:926-928.
FULL TEXT